214 related articles for article (PubMed ID: 23106934)
1. Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study.
Chiroli S; Mattin C; Belozeroff V; Perrault L; Mitchell D; Gioni I
BMC Nephrol; 2012 Oct; 13():140. PubMed ID: 23106934
[TBL] [Abstract][Full Text] [Related]
2. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.
Floege J; Kim J; Ireland E; Chazot C; Drueke T; de Francisco A; Kronenberg F; Marcelli D; Passlick-Deetjen J; Schernthaner G; Fouqueray B; Wheeler DC;
Nephrol Dial Transplant; 2011 Jun; 26(6):1948-55. PubMed ID: 20466670
[TBL] [Abstract][Full Text] [Related]
3. Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients.
Schumock GT; Andress D; E Marx S; Sterz R; Joyce AT; Kalantar-Zadeh K
Curr Med Res Opin; 2008 Nov; 24(11):3037-48. PubMed ID: 18826748
[TBL] [Abstract][Full Text] [Related]
4. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
5. [Total parathyroidectomy in treatment of Sagliker syndrome in 10 cases of hemodialysing patients with secondary hyperparathyroidism].
Zhang L; Yao L; Hua Z; Bian WJ; Li WG
Zhonghua Nei Ke Za Zhi; 2011 Jul; 50(7):562-7. PubMed ID: 22041265
[TBL] [Abstract][Full Text] [Related]
6. Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.
Zitt E; Jäger C; Rosenkranz AR; Eigner M; Kodras K; Kovarik J; Graf H; Pétavy F; Horn S; Watschinger B
Wien Klin Wochenschr; 2011 Jan; 123(1-2):45-52. PubMed ID: 21253777
[TBL] [Abstract][Full Text] [Related]
7. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
[TBL] [Abstract][Full Text] [Related]
8. Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study.
Asada S; Yokoyama K; Miyakoshi C; Fukuma S; Endo Y; Wada M; Nomura T; Onishi Y; Fukagawa M; Fukuhara S; Akizawa T
Clin Exp Nephrol; 2020 Jul; 24(7):630-637. PubMed ID: 32236781
[TBL] [Abstract][Full Text] [Related]
9. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].
Reichel H; Braun J
Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622
[TBL] [Abstract][Full Text] [Related]
10. Healthcare use and costs before and after parathyroidectomy in patients on dialysis.
Belozeroff V; Cooper K; Hess G; Chang CL
BMC Health Serv Res; 2013 Jul; 13():248. PubMed ID: 23819622
[TBL] [Abstract][Full Text] [Related]
11. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
Reichel H
Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
[TBL] [Abstract][Full Text] [Related]
12. [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].
Mpio I; Boumendjel N; Karaaslan H; Arkouche W; Lenz A; Cardozo C; Cardozo J; Pastural-Thaunat M; Fouque D; Silou J; Attaf D; Laville M
Nephrol Ther; 2011 Jul; 7(4):229-36. PubMed ID: 21353659
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
[TBL] [Abstract][Full Text] [Related]
14. Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort.
Lamina C; Kronenberg F; Stenvinkel P; Froissart M; Forer L; Schönherr S; Wheeler DC; Eckardt KU; Floege J
Nephrol Dial Transplant; 2020 Mar; 35(3):478-487. PubMed ID: 31006013
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.
Eandi M; Pradelli L; Iannazzo S; Chiroli S; Pontoriero G
Pharmacoeconomics; 2010; 28(11):1041-54. PubMed ID: 20936886
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
[TBL] [Abstract][Full Text] [Related]
18. Progression of Vascular Calcification and Clinical Outcomes in Patients Receiving Maintenance Dialysis.
Zhang H; Li G; Yu X; Yang J; Jiang A; Cheng H; Fu J; Liang X; Liu J; Lou J; Wang M; Xing C; Zhang A; Zhang M; Xiao X; Yu C; Wang R; Wang L; Chen Y; Guan T; Peng A; Chen N; Hao C; Liu B; Wang S; Shen D; Jia Z; Liu Z;
JAMA Netw Open; 2023 May; 6(5):e2310909. PubMed ID: 37126347
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients.
Gagné ER; Ureña P; Leite-Silva S; Zingraff J; Chevalier A; Sarfati E; Dubost C; Drüeke TB
J Am Soc Nephrol; 1992 Oct; 3(4):1008-17. PubMed ID: 1450363
[TBL] [Abstract][Full Text] [Related]
20. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
